Hansa Biopharma announced that its Phase 3 ConfIdeS trial results for kidney transplantation in highly sensitized patients will be presented at the American Transplant Congress on June 22, 2026. The presentation will detail 12-month outcomes, including improved kidney function (eGFR) and safety data for imlifidase, a treatment that helps patients with difficult-to-match antibodies receive transplants. This enzyme therapy is conditionally approved in Europe and other regions, with FDA review ongoing in the US. The data could support wider adoption of imlifidase to improve transplant access and outcomes for patients with complex immune profiles.
Flowers Foods shares fell 13.3% following a disappointing Q1 earnings and revenue report. Despite the setbacks, management is focused on a turnaround strategy involving cost-cutting, operational simplification, and discontinuing underperforming produ...
The US Department of Justice has seized over 1 bitcoin linked to Wei Gong, a Chinese national arrested for importing synthetic drugs into Georgia. The case involved tracing Binance account records, blockchain analysis, and cooperation with Chinese au...
TruBridge, Inc. disclosed errors in its previously issued financial statements for 2023 and 2024, leading to a late filing of its 2025 annual report. The errors involve revenue recognition, contract costs, stock-based compensation, and capitalized so...
BNB Chain has introduced the Agent Survival Pack, a bundle of six AI infrastructure projects that allows autonomous AI agents to manage and pay their operational costs directly on the BNB Smart Chain using BNB or BEP-20 tokens. This innovation uses t...
JOYY Inc. posted a 12.4% year-over-year revenue increase to $555.7 million in Q1 2026, driven by growth in social entertainment, BIGO Ads, and SHOPLINE e-commerce segments. BIGO Ads revenue surged 55.6%, while SHOPLINE grew 16.1%. The company also an...
